ARMP

Over the past six months, Armata Pharmaceuticals announced the commissioning of its cGMP phage manufacturing facility and filed a Follow-on Equity Offering for $100 million. The company concluded an End-of-Phase 2 meeting with the FDA and plans to advance AP-SA02 into a Phase 3 study. Armata received FDA Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation for AP-SA02. The company delayed its Q4 and full-year 2025 financial results, later reporting a net loss of $124.3 million. Armata announced its 2026 annual meeting of stockholders and appointed Daniel B. Gilmer to its Board of Directors. The stock price has shown significant volatility, with a 52-week high of $16.34 and a 52-week low of $1.17.